Your browser doesn't support javascript.
loading
The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer.
Akbari, M R; Wallis, C J D; Toi, A; Trachtenberg, J; Sun, P; Narod, S A; Nam, R K.
Affiliation
  • Akbari MR; 1] Women's College Research Institute, Women's College Hospital, 790 Bay St, Toronto, ON M5G 1N8, USA [2] Dalla Lana School of Public Health, University of Toronto, 155 College St, Toronto, ON M5T 3M7, USA.
  • Wallis CJ; 1] Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, USA [2] Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, USA.
  • Toi A; Division of Radiology, University of Toronto, 155 College St, Toronto, ON M5T 3M7, USA.
  • Trachtenberg J; 1] Division of Urology, University of Toronto, 155 College St, Toronto, ON M5T 3M7, USA [2] Princess Margaret Hospital, 610 University Ave, Toronto, ON M5T 2M9, USA.
  • Sun P; Women's College Research Institute, Women's College Hospital, 790 Bay St, Toronto, ON M5G 1N8, USA.
  • Narod SA; 1] Women's College Research Institute, Women's College Hospital, 790 Bay St, Toronto, ON M5G 1N8, USA [2] Dalla Lana School of Public Health, University of Toronto, 155 College St, Toronto, ON M5T 3M7, USA.
  • Nam RK; 1] Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, USA [2] Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, USA.
Br J Cancer ; 111(6): 1238-40, 2014 Sep 09.
Article in En | MEDLINE | ID: mdl-25101567
ABSTRACT

BACKGROUND:

Men with a BRCA2 mutation face an increased risk of prostate cancer. These cancers tend to have an aggressive nature and it has not yet been demonstrated that regular screening of BRCA2 carriers is associated with improved survival.

METHODS:

We identified 4187 men who underwent a prostate cancer biopsy for an elevated PSA or an abnormal digital rectal examination between 1998 and 2010. We screened the BRCA2 gene in its entirety for mutations and we followed the men for death from prostate cancer until December 2012.

RESULTS:

The 12-year prostate cancer-specific survival rate was 94.3% for men without a BRCA2 mutation and was 61.8% for men with a mutation (P<10(-4); log-rank test).

CONCLUSIONS:

The survival of men with screen-detected prostate cancer and a BRCA2 mutation is much poorer than expected.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostate / Prostatic Neoplasms / BRCA2 Protein Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2014 Document type: Article Affiliation country: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostate / Prostatic Neoplasms / BRCA2 Protein Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2014 Document type: Article Affiliation country: Estados Unidos